Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

When are bioavailability studies required? A German proposal

C H Gleiter1, U Klotz, J Kuhlmann

  • 1Abteilung Klinische Pharmakologie der Universität Göttingen, Germany.

Journal of Clinical Pharmacology
|November 10, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.

Clinical research in cardiology supplements·2019
Same author

Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.

Atherosclerosis. Supplements·2017
Same author

Erratum to: The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.

Clinical research in cardiology supplements·2017
Same author

The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.

Clinical research in cardiology supplements·2017
Same author

Age-related prevalence of cross-reactive antibodies against influenza A(H3N2) variant virus, Germany, 2003 to 2010.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2015
Same author

[Herbal medicines: when to use or not to use?].

Der Internist·2014
Same journal

AI is Excellent at the Discovery and Identification of Unrecognized Scientific Knowledge but There Is No Evidence That AI Can Create New Scientific Knowledge.

Journal of clinical pharmacology·2026
Same journal

Ketamine Dosing Across Clinical Indications: A Narrative Review Organized by Proposed NMDA-Related Mechanisms.

Journal of clinical pharmacology·2026
Same journal

Flip-Flop Pharmacokinetics in Pregnancy and the Future of Obstetric Pharmacology.

Journal of clinical pharmacology·2026
Same journal

Correction to "A Phase 1 Study Evaluating the Pharmacokinetics and Safety of Avacopan in Participants With End-Stage Kidney Disease on Hemodialysis".

Journal of clinical pharmacology·2026
Same journal

Street Pharmacology: The Mechanistic Basis of Clinical Pharmacology Underlying the Microdosing Method of Buprenorphine-Naloxone With a Focus on the Unhoused Population.

Journal of clinical pharmacology·2026
Same journal

Ontology-Enhanced Deep Learning for Mechanistic Prediction of Drug-Drug Interactions: A Clinically Interpretable Framework.

Journal of clinical pharmacology·2026
See all related articles

The German drug authority (BfArM) developed a decision tree to determine if bioavailability/bioequivalence studies are needed for drugs. This approach, based on drug properties, is widely adopted internationally.

Area of Science:

  • Pharmacology
  • Drug Regulation
  • Pharmaceutical Science

Background:

  • The German Federal Institute for Drugs and Medical Devices (BfArM) established guidelines to assess the necessity of bioavailability and bioequivalence studies.
  • These guidelines utilize a decision tree incorporating pharmacodynamic, pharmacokinetic, and physicochemical drug characteristics.

Purpose of the Study:

  • To review the original BfArM decision tree for determining bioavailability/bioequivalence study requirements.
  • To discuss its application in regulatory practice and its international adoption.

Main Methods:

  • Analysis of the BfArM decision tree criteria (pharmacodynamic, pharmacokinetic, physicochemical).
  • Review of historical application and expert panel deliberations.
  • Examination of adoption by European and international bodies (CPMP, WHO).

Related Experiment Videos

Main Results:

  • The BfArM decision tree has guided German regulatory authorities for over a decade.
  • Key principles of the decision tree have been integrated into European and WHO guidelines on multisource pharmaceutical products.
  • The article provides examples of drug assessments using the decision tree.

Conclusions:

  • The BfArM decision tree provides a robust framework for regulatory assessment of bioavailability/bioequivalence study needs.
  • Its principles are foundational to current international standards for drug interchangeability.
  • The current German procedure reflects established regulatory practice for these critical drug evaluations.